Investors in Nahdi Medical Company (TADAWUL:4164) had a good week, as its shares rose 8.6% to close at ر.س90.05 following the release of its third-quarter results. It was a workmanlike result, with revenues of ر.س2.7b coming in 3.7% ahead of expectations, and statutory earnings per share of ر.س6.39, in line with analyst appraisals. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Taking into account the latest results, the most recent consensus for Nahdi Medical from nine analysts is for revenues of ر.س11.7b in 2027. If met, it would imply a decent 8.5% increase on its revenue over the past 12 months. Per-share earnings are expected to ascend 10% to ر.س6.76. Yet prior to the latest earnings, the analysts had been anticipated revenues of ر.س11.7b and earnings per share (EPS) of ر.س6.85 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
View our latest analysis for Nahdi Medical
There were no changes to revenue or earnings estimates or the price target of ر.س116, suggesting that the company has met expectations in its recent result. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Nahdi Medical, with the most bullish analyst valuing it at ر.س142 and the most bearish at ر.س100.00 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 6.7% growth on an annualised basis. That is in line with its 5.9% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 5.6% annually. So although Nahdi Medical is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at ر.س116, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Nahdi Medical analysts - going out to 2028, and you can see them free on our platform here.
You should always think about risks though. Case in point, we've spotted 1 warning sign for Nahdi Medical you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.